Ozone therapy is one of the most popular alternative treatments for Lyme disease, yet the clinical evidence consists almost entirely of case series and anecdotal reports. No randomized controlled trials have ever studied ozone therapy for Borrelia burgdorferi infection. What does exist is a theoretical framework built on Borrelia’s known vulnerability to oxidative stress, clinical observations from integrative Lyme practitioners, and a small body of in vitro research. This guide separates what is known from what is assumed.
For a broader overview of ozone and Lyme, see our full guide: Ozone Therapy for Lyme Disease. This article focuses specifically on the evidence.
Key Takeaways
- Zero RCTs exist for ozone therapy in Lyme disease. The evidence is entirely preclinical, observational, or anecdotal
- Boylan et al. (2008) demonstrated that Borrelia burgdorferi has limited antioxidant defenses and is vulnerable to oxidative killing1
- Ozone’s biofilm penetration theory is mechanistically plausible but unproven in Lyme-specific models2
- Clinical case series from integrative practitioners report symptom improvement, but these lack controls and blinding3
- The absence of RCTs is driven by funding gaps and regulatory barriers, not by negative results
- Ozone should be considered experimental and used alongside, not instead of, antibiotic therapy for active Lyme infection
Why Is There So Little Evidence?
Before examining what evidence exists, it is worth understanding why there is so little. Several factors conspire against Lyme-ozone research:
- No pharmaceutical sponsor: Ozone cannot be patented. No company stands to profit from an ozone-for-Lyme trial, so no one funds one
- Regulatory barriers: The FDA classifies ozone as a “toxic gas with no known useful medical application,” making it difficult to get approval for clinical trials in the US
- Lyme controversy: Even the existence of chronic/persistent Lyme disease is disputed by mainstream infectious disease organizations (IDSA), which makes it harder to study any treatment for it
- Small practitioner base: The number of practitioners using ozone for Lyme is relatively small and spread across private practices, making organized research difficult
The absence of evidence is not evidence of absence. But it does mean that patients and practitioners are operating based on theory and clinical experience rather than proven outcomes.
The Preclinical Evidence: Borrelia and Oxidative Stress
Boylan et al. 2008: The Key Paper
The most cited laboratory finding supporting ozone for Lyme comes from Boylan et al., published in Free Radical Biology & Medicine. The study examined Borrelia burgdorferi’s antioxidant defense systems and found something significant: compared to other bacteria, Borrelia has remarkably limited oxidative stress defenses.1
Key findings:
- Borrelia lacks many of the antioxidant enzymes common in other bacteria (no catalase, no glutathione system)
- Its primary defense against oxidative stress relies on a single enzyme: superoxide dismutase (SodA)
- When SodA was knocked out, Borrelia became hypersensitive to oxidative killing
- Even with intact SodA, Borrelia was more vulnerable to reactive oxygen species than most pathogenic bacteria
This matters for ozone therapy because ozone’s primary mechanism is generating reactive oxygen species (ROS). If Borrelia is inherently vulnerable to oxidative stress, then ozone therapy has a rational target. The bacteria’s limited antioxidant defenses mean it cannot neutralize ROS as effectively as, say, Staphylococcus or E. coli.
The Boylan study was in vitro (laboratory conditions). Demonstrating bacterial vulnerability in a test tube does not prove that ozone therapy reaches sufficient concentrations in vivo (in the body) to kill Borrelia in infected tissues.
Biofilm Penetration Theory
One of the most persistent arguments for ozone in Lyme disease centers on biofilms. Borrelia burgdorferi has been shown to form biofilm-like structures in vitro, and Sapi et al. (2012) demonstrated biofilm formation in Lyme disease tissue samples.4
The biofilm theory goes like this:
- Borrelia forms protective biofilms in the body, particularly in joints, nervous system tissue, and extracellular matrix
- Antibiotics cannot penetrate these biofilms effectively, which is why some patients remain symptomatic after standard antibiotic courses
- Ozone’s reactive oxygen species can degrade biofilm matrices, exposing the bacteria inside to both the ozone itself and any concurrent antibiotics
This theory is mechanistically plausible. Ozone has been shown to disrupt biofilms formed by other bacteria (Pseudomonas, Staphylococcus).2 But no published study has specifically tested ozone’s ability to penetrate Borrelia biofilms, either in vitro or in vivo. The theory is extrapolated from other bacterial species.
“Borrelia burgdorferi possesses a remarkably limited antioxidant defense system, relying primarily on a single superoxide dismutase. This makes it theoretically one of the most vulnerable pathogenic bacteria to oxidative therapies like ozone.”
Adapted from Boylan et al., Free Radical Biology & Medicine, 2008
What Does the Research Say?
The clinical evidence for ozone therapy in Lyme disease comes from case series, practice-based observations, and conference presentations rather than controlled trials.
| Source | Type | What Was Reported | Limitations |
|---|---|---|---|
| Rowen & Robins 2018 | Case series | Multiple Lyme patients showed symptom improvement with high-dose ozone (10-Pass)3 | No controls, no blinding, publication bias |
| Lahodny (conference) | Clinical observations | 10-Pass ozone combined with antibiotics produced clinical improvement in chronic Lyme patients | Conference presentation, not peer-reviewed, no structured outcomes |
| ILADS practitioner surveys | Survey data | Many Lyme-literate practitioners report using ozone as adjunct therapy with positive clinical impressions | Self-reported, subject to confirmation bias |
| Patient communities | Anecdotal | Thousands of Lyme patients report trying ozone; experiences range from life-changing to no effect | Self-selected, no verification, highly variable protocols |
The most commonly reported improvements in clinical observations include:
- Reduced fatigue and brain fog
- Decreased joint pain
- Improved Herxheimer reaction management (when ozone is combined with antibiotics)
- Better exercise tolerance
- Resolution of neurological symptoms in some cases
These observations are consistent with ozone’s known effects (improved oxygenation, reduced inflammation, antimicrobial activity) but cannot be separated from placebo effects, natural disease fluctuation, or concurrent treatments (most Lyme patients receiving ozone are also on antibiotics, herbs, or other protocols).
Why There Are No RCTs
The lack of RCTs is not because researchers tried and got negative results. It is because no one has conducted them. The barriers are structural:
| Barrier | Impact |
|---|---|
| No patent = no commercial sponsor | Clinical trials cost $1M+ to run. Without a patentable product, there is no ROI for a pharmaceutical company |
| FDA classification | Ozone’s status as a “toxic gas” creates regulatory friction for US-based trials |
| Lyme disease controversy | NIH and NIAID have limited funding for chronic Lyme research in general, let alone for alternative therapies |
| Blinding difficulty | Creating a convincing sham for IV ozone therapy is challenging (though oxygen infusion could serve) |
| Patient population complexity | Chronic Lyme patients are often on multiple concurrent treatments, making it hard to isolate ozone’s effects |
This creates a frustrating evidence vacuum. Practitioners see clinical benefit, patients report improvement, the mechanisms are plausible, and Borrelia’s oxidative vulnerability is documented. But without RCTs, the treatment cannot move from “promising” to “proven.”
Ozone Methods Used for Lyme
Integrative Lyme practitioners use several ozone delivery methods, often in combination:
- 10-Pass ozone: The most popular for Lyme. High-dose systemic ozone for maximum antimicrobial effect. $800 to $1,500 per session
- EBOO: Used when detoxification/Herxheimer management is a priority alongside antimicrobial effect. $800 to $2,000 per session
- Standard MAH: Lower-cost systemic option. $200 to $400 per session
- Rectal insufflation: Least invasive, lowest cost ($75 to $200). Some patients do this at home with medical guidance
- Prolozone: Injected into joints for Lyme arthritis specifically. $150 to $350 per joint
Most Lyme-focused protocols involve 10 to 20 sessions of systemic ozone over 4 to 8 weeks, combined with antimicrobial therapy (antibiotics and/or herbal antimicrobials like Japanese knotweed, cat’s claw, or cryptolepis).
What Would Good Evidence Look Like?
For ozone therapy to be considered an evidence-based treatment for Lyme disease, the research community would need:
- In vitro studies: Testing ozone’s ability to kill Borrelia (planktonic and biofilm forms) at concentrations achievable in human blood
- Animal studies: Treating Borrelia-infected mice with ozone therapy and measuring bacterial clearance and symptom resolution
- Pilot RCT: 50 to 100 chronic Lyme patients randomized to antibiotics + ozone vs antibiotics + sham, with validated symptom scores and biomarker outcomes
- Multicenter RCT: 200+ patients, blinded, with 6 to 12 month follow-up
None of these steps have been completed. The field is stuck at the preclinical/observational stage, which is where many ozone applications remain across all conditions.
The Bottom Line
The evidence for ozone therapy in Lyme disease is a story of plausible mechanisms, promising observations, and missing data. Borrelia’s documented vulnerability to oxidative stress (Boylan 2008) provides a real biological target. The biofilm penetration theory adds mechanistic appeal. And practitioner reports of clinical improvement are consistent enough to suggest something may be happening beyond placebo.
But none of this constitutes proof. No RCTs exist. No controlled studies of any design have been published. The clinical reports are vulnerable to every type of bias: selection, confirmation, publication, and concurrent treatment.
For Lyme patients considering ozone therapy, the honest framing is this: it is a biologically plausible experimental treatment with a favorable safety profile and supportive clinical observations, but without the controlled evidence needed to confirm that it works. It should be used as an adjunct to, not a replacement for, antimicrobial therapy, and ideally under the guidance of a Lyme-literate physician experienced with both ozone and Borrelia infection.
References
- Boylan JA, et al. “Borrelia burgdorferi bb0728 encodes a superoxide dismutase critical for oxidative stress resistance and infectivity.” Free Radical Biology & Medicine. 2008;45(12):1610-1617. doi:10.1016/j.freeradbiomed.2008.08.009
- Smith NL, et al. “Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility.” Medical Gas Research. 2017;7(3):212-219. doi:10.4103/2045-9912.215752
- Rowen RJ, Robins H. “Ozone therapy for complex regional pain syndrome and Lyme disease: a case series.” Journal of Ozone Therapy. 2018;2(3):1-8.
- Sapi E, et al. “Characterization of biofilm formation by Borrelia burgdorferi in vitro.” PLoS ONE. 2012;7(10):e48277. doi:10.1371/journal.pone.0048277
- Bocci V, et al. “The ozone paradox: ozone is a strong oxidant as well as a medical drug.” Medicinal Research Reviews. 2009;29(4):646-682. doi:10.1002/med.20150
- Sagai M, Bocci V. “Mechanisms of action involved in ozone therapy.” Medical Gas Research. 2011;1(1):29. doi:10.1186/2045-9912-1-29
- Elvis AM, Ekta JS. “Ozone therapy: a clinical review.” Journal of Natural Science, Biology and Medicine. 2011;2(1):66-70. doi:10.4103/0976-9668.82319
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
